TY - JOUR
T1 - Serum Müllerian Inhibiting Substance/Anti-Müllerian Hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology
AU - Chang, Henry L.
AU - Pahlavan, Nima
AU - Halpern, Elkan F.
AU - MacLaughlin, David T.
N1 - Funding Information:
The authors would like to thank Dr. Patricia K. Donahoe for her intellectual input and critical reading of this manuscript. HLC was supported by NIH/MGH T32 in Cancer Biology T32CA071345-11. DTM was supported by NIH CA17393-30, The Ovarian Cancer Research Fund, the McBride Family Fund. and the Commons Development Group, Inc.
PY - 2009/7
Y1 - 2009/7
N2 - Objectives: Granulosa cell tumors (GCTs) comprise 2-5% of ovarian tumors. Serum Müllerian Inhibiting Substance (MIS, also known as anti-Müllerian hormone, or AMH) levels have been validated as a marker of GCT recurrence and progression. There has been little correlation between serum MIS/AMH levels and several clinical parameters in GCTs, including tumor burden. We have performed a retrospective review correlating aggregate tumor mass as reported by pathologic examination or by radiology with serum MIS/AMH levels drawn on the date of examination. Methods: We retrospectively identified 32 GCT patients at our institution over the last 15 years who had serum MIS/AMH measurements. Patients who had serum MIS/AMH measurements within three days of surgery or on the same day as abdominal computerized tomography scan (CT) or magnetic resonance imaging (MRI) were further evaluated. Results: We found a significant direct correlation between patient serum MIS/AMH levels and gross aggregate tumor mass determined by pathology (slope = 15.4 ± 6.06, r = 0.65, p < 0.04) or by radiographic aggregate tumor mass for all data points identified (slope = 0.07 ± 0.03, r = 0.33, p < 0.04) and after correcting for selection bias (slope = 1.45 ± 0.17, r = 0.93, p < 0.01). We also identified a significant difference between serum MIS/AMH levels between samples drawn the same day as negative and positive abdominal CT or MRI scans (8.16 ± 1.54 vs. 158.7 ± 32.2 ng/ml, p < 0.0001). Conclusions: These data indicate a significant direct correlation between serum MIS/AMH levels and both gross and radiographic aggregate tumor mass in GCT patients. Together with the current literature, the present data argue for a more prominent role for serum MIS/AMH in the management of GCTs.
AB - Objectives: Granulosa cell tumors (GCTs) comprise 2-5% of ovarian tumors. Serum Müllerian Inhibiting Substance (MIS, also known as anti-Müllerian hormone, or AMH) levels have been validated as a marker of GCT recurrence and progression. There has been little correlation between serum MIS/AMH levels and several clinical parameters in GCTs, including tumor burden. We have performed a retrospective review correlating aggregate tumor mass as reported by pathologic examination or by radiology with serum MIS/AMH levels drawn on the date of examination. Methods: We retrospectively identified 32 GCT patients at our institution over the last 15 years who had serum MIS/AMH measurements. Patients who had serum MIS/AMH measurements within three days of surgery or on the same day as abdominal computerized tomography scan (CT) or magnetic resonance imaging (MRI) were further evaluated. Results: We found a significant direct correlation between patient serum MIS/AMH levels and gross aggregate tumor mass determined by pathology (slope = 15.4 ± 6.06, r = 0.65, p < 0.04) or by radiographic aggregate tumor mass for all data points identified (slope = 0.07 ± 0.03, r = 0.33, p < 0.04) and after correcting for selection bias (slope = 1.45 ± 0.17, r = 0.93, p < 0.01). We also identified a significant difference between serum MIS/AMH levels between samples drawn the same day as negative and positive abdominal CT or MRI scans (8.16 ± 1.54 vs. 158.7 ± 32.2 ng/ml, p < 0.0001). Conclusions: These data indicate a significant direct correlation between serum MIS/AMH levels and both gross and radiographic aggregate tumor mass in GCT patients. Together with the current literature, the present data argue for a more prominent role for serum MIS/AMH in the management of GCTs.
KW - Adult granulosa cell tumor
KW - Anti-Müllerian hormone
KW - Müllerian Inhibiting Substance
KW - Ovarian sex-cord stromal tumor
UR - http://www.scopus.com/inward/record.url?scp=67349115264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349115264&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2009.02.023
DO - 10.1016/j.ygyno.2009.02.023
M3 - Article
C2 - 19359032
AN - SCOPUS:67349115264
SN - 0090-8258
VL - 114
SP - 57
EP - 60
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -